Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with ulcerative colitis (UC), alterations of the intestinal microbiota, termed dysbiosis, have been postulated to contribute to intestinal inflammation. Fecal microbiota transplantation (FMT) has been used as effective therapy for recurrent Clostridium difficile colitis also caused by dysbiosis. The aims of the present study were to investigate if patients with UC benefit from FMT and if dysbiosis can be reversed. METHODS: Six patients with chronic active UC nonresponsive to standard medical therapy were treated with FMT by colonoscopic administration. Changes in the colonic microbiota were assessed by 16S rDNA-based microbial community profiling using high-throughput pyrosequencing from mucosal and stool samples. RESULTS: All patients experienced short-term clinical improvement within the first 2 weeks after FMT. However, none of the patients achieved clinical remission. Microbiota profiling showed differences in the modification of the intestinal microbiota between individual patients after FMT. In 3 patients, the colonic microbiota changed toward the donor microbiota; however, this did not correlate with clinical response. On phylum level, there was a significant reduction of Proteobacteria and an increase in Bacteroidetes after FMT. CONCLUSIONS: FMT by a single colonoscopic donor stool application is not effective in inducing remission in chronic active therapy-refractory UC. Changes in the composition of the intestinal microbiota were significant and resulted in a partial improvement of UC-associated dysbiosis. The results suggest that dysbiosis in UC is at least in part a secondary phenomenon induced by inflammation and diarrhea rather than being causative for inflammation in this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These reports were followed by a number of small studies of FMT in children and adults with UC, CD, and pouchitis with mixed results.64–72”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [69]
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913 · cited 1×
“, 16S rDNA) in combination with highthroughput sequencing techniques that enabled culture-independent surveys of human gut microbes.(32) Using these techniques, remarkable changes in the human gut microbiota in patients with IBD have been observed.”
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762 · cited 1×
“5.(25) Contaminant (human) sequences and singletons were manually removed.”
BackgroundFrank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611 · cited 2×
“Using these techniques, remarkable changes in the human gut microbiota in patients with IBD have been observed.(6,30,33,34) These changes, also termed dysbiosis, are thought to be involved in the pathogenesis of IBD.”
BackgroundMethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 3×
“Changes of the intestinal microbiota after FMT have so far been studied only in recurrent CDI.(13,43) Successful FMT in CDI was associated with an increase in bacterial diversity and richness,(13,43) an increase of Bacteroidetes, Firmicutes, and butyrate-producing bacteria such as Lachnospiraceae, and a decrease in Pr…”
BackgroundCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026 · cited 1×
“During control visits, the clinical condition and endoscopic activity of UC were judged using the Mayo score.(20) A reduction of the total Mayo score by $3 points was considered as a clinical response, whereas a drop of the Mayo score to #2 points was considered as remission.”
MethodFord Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713
Research works printed but not linked: 1
- Lee, 2010, 330, 1768
Cited by
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
The gut microbiome in health and in disease
Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000139 · Cited by 1,682
“Early efforts to utilize FMT for the treatment of IBD have been rather disappointing [45,46].”
BackgroundDisease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease
Norman, J. M., Handley, S. A., Baldridge, M. T., Droit, L., Liu, C. Y., Keller, B. C., Kambal, A., Monaco, C. L., Zhao, G., Fleshner, P., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.002 · Cited by 1,285
“However, early attempts at curing bacterial dysbiosis in UC through fecal transplantation have not proven successful (Angelberger et al., 2013; Kump et al., 2013), perhaps due to the instability of the donor microbiome in IBD patients.”
BackgroundParamsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Self-citationThe gut microbiota and inflammatory bowel disease
Matsuoka, K., & Kanai, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0454-4 · Cited by 804
“Two prospective studies of FMT for adult UC patients were recently published [57, 58].”
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
“Moreover, two recently published prospective studies in which FMT was used for adult UC patients failed to achieve clinical remission after FMT, though in most of the patients’, significant structural changes were observed in the gut microbiota [263,264].”
ResultShen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646
Kelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
The role of the gut microbiome in systemic inflammatory disease
Clemente, J. C., Manasson, J., & Scher, J. U. (2018) · BMJ · doi:10.1136/bmj.j5145 · Cited by 568
Understanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561
Development and maintenance of intestinal regulatory T cells
Tanoue, T., Atarashi, K., & Honda, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.36 · Cited by 553
Bian, X., Wu, W., Yang, L., Lv, L., Wang, Q., Li, Y., Ye, J., Fang, D., Wu, J., Jiang, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02259 · Cited by 530
“Four randomized controlled trials (RCTs) along with several cases have showed the efficacy of FMT to induce remission in active UC patients (Angelberger et al., 2013; Kump et al., 2013; Kunde et al., 2013; Cui et al., 2015; Moayyedi et al., 2015; Ren et al., 2015; Rossen et al., 2015; Suskind et al., 2015; Wei et al.,…”
BackgroundColman, R. J., & Rubin, D. T. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.006 · Cited by 475
“…et al. (2012)27 4 CD Medically-refractory 200 g feces NJ infusion NR 3× in 36 h Healthy donor 2 months 2 Kunde et al. (2013)23 10 (−1 a) UC Mild–moderate 90–113 g/250 ml Enema up to (4 × 60ml)/day NR ×5 days Parents 6 weeks 3 Kump et al. (2013)22 6 UC Therapy-refractory 100–150 g/200–350 ml saline–”
BackgroundIntestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease
Weingarden, A. R., & Vaughn, B. P. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1290757 · Cited by 463
Schaubeck, M., Clavel, T., Calasan, J., Lagkouvardos, I., Haange, S. B., Jehmlich, N., Basic, M., Dupont, A., Hornef, M., Bergen, M. V., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309333 · Cited by 447
Paramsothy, S., Paramsothy, R., Rubin, D. T., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., & Castaño-Rodríguez, N. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx063 · Cited by 436
Systematic Review: Adverse Events of Fecal Microbiota Transplantation
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161174 · Cited by 409
“Borody, 2003 [67] Sore throat 3 8 Definitely Nasojejunal tube Lower gastrointestinal routes Kump, 2013 [68] Fever; Temporary increase of CRP and IL-6; Increase in stool frequency 1 6 Probably Colonoscopy Zhang, 2013 [69] Severe cold 1 1 Possibly Colonoscopy Quera, 2013 [44] Fever; Bacteremia 1 1 Probably Colonoscopy K…”
Hold, G. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1192 · Cited by 365
Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Guo, X. Y., Liu, X. J., & Hao, J. Y. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12849 · Cited by 336
Vermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., Ferrante, M., Van Assche, G., Rutgeerts, P., & Raes, J. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv203 · Cited by 311
Costello, S. P., Soo, W., Bryant, R. V., Jairath, V., Hart, A. L., & Andrews, J. M. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14173 · Cited by 258
Bashir, M., Prietl, B., Tauschmann, M., Mautner, S. I., Kump, P. K., Treiber, G., Wurm, P., Gorkiewicz, G., Högenauer, C., & Pieber, T. R. (2016) · European Journal of Nutrition · doi:10.1007/s00394-015-0966-2 · Cited by 254
“[28] and pooled and sequenced using the GS FLX Titanium Sequencing Kit XLR70 (Roche 454 Life Science, Branford, CT, USA) according to manufacturer’s instructions.”
MethodSelf-citationFecal microbiota transplantation as novel therapy in gastroenterology: A systematic review
Rossen, N. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5359 · Cited by 242
Treatment of IBD: Where We Are and Where We Are Going
Bernstein, C. N. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.357 · Cited by 235
Koskinen, K., Pausan, M. R., Perras, A. K., Beck, M., Bang, C., Mora, M., Schilhabel, A., Schmitz, R., & Moissl-Eichinger, C. (2017) · mBio · doi:10.1128/mbio.00824-17 · Cited by 236
“For biopsy specimen collection, 11 volunteers underwent gastroduodenoscopy, followed by colonoscopy on the next day (60, 61).”
MethodVindigni, S. M., Zisman, T. L., Suskind, D. L., & Damman, C. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644242 · Cited by 229
The microbiota in inflammatory bowel disease: Current and therapeutic insights
Lane, E. R., Zisman, T., & Suskind, D. (2017) · Journal of Inflammation Research · doi:10.2147/jir.s116088 · Cited by 226
“69,102,103 106 There are currently insufficient data to support the use of FMT for treatment of CD, but given the small number of studies and small patient sample sizes, additional studies are required to draw definitive conclusions on the efficacy of FMT for induction or maintenance of remission…”
Fuentes, S., Rossen, N. G., van der Spek, M. J., Hartman, J. H. A., Huuskonen, L., Korpela, K., Salojärvi, J., Aalvink, S., de Vos, W. M., D’Haens, G. R., et al. (2017) · The ISME Journal · doi:10.1038/ismej.2017.44 · Cited by 223
“FMT has been shown to have a role on colitis activity in several case series (Angelberger et al., 2012; Borody et al., 2012; Kump et al., 2013; Kunde et al., 2013; Aroniadis et al., 2016), as well as three randomized controlled trials (Moayyedi et al., 2015; Rossen et al., 2015; Paramsothy et al.,…”
MethodThe intestinal microbiota: its role in health and disease
Biedermann, L., & Rogler, G. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-014-2476-2 · Cited by 211
“While some authors and small case reports/series reported a clear benefit, others could not find a beneficial effect and even saw adverse events in IBD patients such as fever or diarrhea [5, 41, 103].”
BackgroundKump, P., Wurm, P., Gröchenig, H. P., Wenzl, H., Petritsch, W., Halwachs, B., Wagner, M., Stadlbauer, V., Eherer, A., Hoffmann, K. M., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14387 · Cited by 196
“Antibiotic pre-treatment was chosen to decrease intestinal colonisation resistance since in a previous study, we observed a large variation in engraftment of the donor microbiota after faecal microbiota transplantation in ulcerative colitis.(12) The antibiotics were chosen because they are nonabsorbable and have a bro…”
BackgroundMethodSelf-citationArias, N., Arboleya, S., Allison, J., Kaliszewska, A., Higarza, S. G., Gueimonde, M., & Arias, J. L. (2020) · Nutrients · doi:10.3390/nu12082340 · Cited by 196
From Stool Transplants to Next-Generation Microbiota Therapeutics
Petrof, E. O., & Khoruts, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.004 · Cited by 186
Adverse events in faecal microbiota transplant: a review of the literature
Baxter, M., & Colville, A. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.10.024 · Cited by 185
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.006 · Cited by 180
“Only few, more recent studies used objective scores to assess the disease activity (Angelberger et al., 2013; Kump et al., 2013; Kunde et al., AC C EP TE D M AN U SC R IP T 2013; Landy et al., 2013; Vaandeplas et al., 2014).”
BackgroundMethodResultInfluentialLinks Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease
Raftery, A. L., Tsantikos, E., Harris, N. L., & Hibbs, M. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02144 · Cited by 176
“While this partially corrects the dysbiotic changes that are associated with UC, these changes were not prolonged and did not translate to a vast clinical improvement (193).”
BackgroundReview article: the gut microbiome in inflammatory bowel disease—avenues for microbial management
McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R., & Hold, G. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14384 · Cited by 176
Song, Y., Garg, S., Girotra, M., Maddox, C., von Rosenvinge, E. C., Dutta, A., Dutta, S., & Fricke, W. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081330 · Cited by 172
“As a result, attempts to treat IBD [31–33], metabolic syndrome [34] and other diseases [35,36] by FMT have been made.”
BackgroundThe Fire Within: Microbes Inflame Tumors
Gagliani, N., Hu, B., Huber, S., Elinav, E., & Flavell, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.006 · Cited by 165
“…the results of the first small studies are conflicting: whereas fecal transplantation was shown to be efficient in children and young adults with ulcerative colitis (Kunde et al., 2013), another study did not show efficacy in patients with chronic active ulcerative colitis (Kump et al., 2013).”
ResultSatokari, R., Mattila, E., Kainulainen, V., & Arkkila, P. E. T. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13009 · Cited by 156
Sood, A., Mahajan, R., Singh, A., Midha, V., Mehta, V., Narang, V., Singh, T., & Singh Pannu, A. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz060 · Cited by 149
Donor Recruitment for Fecal Microbiota Transplantation
Paramsothy, S., Borody, T. J., Lin, E., Finlayson, S., Walsh, A. J., Samuel, D., van den Bogaerde, J., Leong, R. W. L., Connor, S., Ng, W., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000405 · Cited by 149
“have a useful primary therapeutic role, though at present there is insufficient evidence to support its use outside a trial setting.(17,18)”
BackgroundCui, B., Li, P., Xu, L., Zhao, Y., Wang, H., Peng, Z., Xu, H., Xiang, J., He, Z., Zhang, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0646-2 · Cited by 148
“[25] reported that FMT did not induce remission in the patients with chronic active UC, and De Leon et al.”
BackgroundLong-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Ding, X. L., Li, Q., Li, P., Zhang, T., Cui, B., Ji, G., Lü, X., & Zhang, F. (2019) · Drug Safety · doi:10.1007/s40264-019-00809-2 · Cited by 145
Goyal, A., Yeh, A., Bush, B. R., Firek, B. A., Siebold, L. M., Rogers, M. B., Kufen, A. D., & Morowitz, M. J. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx035 · Cited by 135
Wang, Z.-K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14805 · Cited by 133
Lopetuso, L. R., Deleu, S., Godny, L., Petito, V., Puca, P., Facciotti, F., Sokol, H., Ianiro, G., Masucci, L., Abreu, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-329948 · Cited by 129
The intestinal microbiome in type 1 diabetes
Dunne, J. L., Triplett, E. W., Gevers, D., Xavier, R., Insel, R., Danska, J., & Atkinson, M. A. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12321 · Cited by 126
Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation.
Marotz, C. A., & Zarrinpar, A. (2016) · PubMed Central · Cited by 151
Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases
Dolan, K. T., & Chang, E. B. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600129 · Cited by 125
Qazi, T., Amaratunga, T., Barnes, E. L., Fischer, M., Kassam, Z., & Allegretti, J. R. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1353848 · Cited by 137
Fang, H., Fu, L., & Wang, J. (2018) · BioMed Research International · doi:10.1155/2018/8941340 · Cited by 123
Wang, W., Xu, A.-L., Li, Z.-C., Li, Y., Xu, S.-F., Sang, H.-C., & Zhi, F. C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0042 · Cited by 135
Wu, R., Xiong, R., Li, Y., Chen, J., & Yan, R. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103062 · Cited by 126
Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis
Shi, Y., Dong, Y., Huang, W., Zhu, D., Mao, H., & Su, P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157259 · Cited by 116
“[34, 35, 41] The reduction of Enterobacteriaceae was demonstrated in 2 trials.”
InfluentialConsensus report: faecal microbiota transfer – clinical applications and procedures
König, J., Siebenhaar, A., Högenauer, C., Arkkila, P., Nieuwdorp, M., Norén, T., Ponsioen, C. Y., Rosien, U., Rossen, N. G., Satokari, R., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13868 · Cited by 114
“If FMT is performed for non-infectious indications antibiotic therapy is usually omitted.(43) A bowel preparation is usually administered to patients the day before the transfer to further reduce”
BackgroundSelf-citationLi, M., Liang, P., Li, Z., Wang, Y., Zhang, G., Gao, H., Wen, S., & Tang, L. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00692 · Cited by 109
Jacob, V., Crawford, C., Cohen-Mekelburg, S., Viladomiu, M., Putzel, G. G., Schneider, Y., Chabouni, F., OʼNeil, S., Bosworth, B., Woo, V., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001132 · Cited by 109
Delivery routes for faecal microbiota transplants: Available, anticipated and aspired
Gulati, M., Singh, S. K., Corrie, L., Kaur, I. P., & Chandwani, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104954 · Cited by 121
Caldeira, L. D. F., Borba, H. H. L., Tonin, F. S., Wiens, A., Fernández-Llimós, F., & Pontarolo, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238910 · Cited by 117
Gut microbiota regulates gut homeostasis, mucosal immunity and influences immune-related diseases
Ding, G., Yang, X., Li, Y., Wang, Y., Du, Y., Wang, M., Ye, R., Wang, J., Zhang, Y., Chen, Y., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05077-y · Cited by 127
“[83].”
Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches
Hansen, J. J., & Sartor, R. B. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-014-0042-7 · Cited by 104
Hourigan, S. K., Chen, L. A., Grigoryan, Z., Laroche, G., Weidner, M., Sears, C. L., & Oliva‐Hemker, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13326 · Cited by 101
Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis
Suskind, D. L., Singh, N., Nielson, H., & Wahbeh, G. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000544 · Cited by 99
“Kump et al also showed that a single administration of FMT via colonoscopy in adult patients with UC did not achieve remission within 90-day follow-up; however, all of the patients did report a temporary improvement within the 2 weeks after FMT, as noted by a decrease in stool frequency (8).”
BackgroundFecal Microbiota Transplantation in Inflammatory Bowel Disease: Beyond the Excitement
Ianiro, G., Bibbò, S., Scaldaferri, F., Gasbarrini, A., & Cammarota, G. (2014) · Medicine · doi:10.1097/md.0000000000000097 · Cited by 98
“Most of these were case reports or case series, whereas 8 publications reported data from open-label trial with a small number of patients treated.(23,31,37,38,43,46,49,50) Really, from the study of Grehan et al,(23) only 1 patient had IBD of a total of 10 patients treated in a small open-label trial.”
BackgroundSystemic effects of gut microbiota and its relationship with disease and modulation
Ho, J. T., Chan, G. C., & Li, J. C. (2015) · BMC Immunology · doi:10.1186/s12865-015-0083-2 · Cited by 93
“none of them achieved complete remission or long-term improvement [34].”
BackgroundInfluentialMechanisms of Microbe–Host Interaction in Crohn’s Disease: Dysbiosis vs. Pathobiont Selection
Buttó, L. F., Schaubeck, M., & Haller, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00555 · Cited by 93
Landy, J., Walker, A. W., Li, J. V., Al-Hassi, H. O., Ronde, E., English, N. R., Mann, E. R., Bernardo, D., McLaughlin, S. D., Parkhill, J., et al. (2015) · Scientific Reports · doi:10.1038/srep12955 · Cited by 92
Wei, Y., Zhu, W., Gong, J., Guo, D., Gu, L., Li, N., & Li, J. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/517597 · Cited by 91
Yao, W., Gong, J., Zhu, W., Tian, H., Ding, C., Gu, L., Li, N., & Li, J. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0869-2 · Cited by 102
“Commercially available probiotics used in treatment of UC mostly include Lactobacillus and Bifidobacterium species, with the anaerobes that comprise most of the intestinal flora having been subjected to less exploration [5].”
BackgroundStandardized Preparation for Fecal Microbiota Transplantation in Pigs
Hu, J. P., Chen, L., Tang, Y., Xie, C., Xu, B., Shi, M. Y., Zheng, W., Zhou, S., Wang, X., Liu, L., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01328 · Cited by 100
“Patients treated with FMT did not experience any serious adverse events (Borody and Khoruts, 2011), except minor symptoms such as slight diarrhea, constipation, vomiting, and abdominal discomfort (Kump et al., 2013; Rossen et al., 2015).”
BackgroundKao, D., Hotte, N., Gillevet, P., & Madsen, K. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000131 · Cited by 87
Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection
Rao, K. K., & Young, V. B. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.009 · Cited by 87
Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?
Serban, D. E. (2015) · Nutrition in Clinical Practice · doi:10.1177/0884533615606898 · Cited by 75
“However, early efforts to use FMT for the treatment of IBD have been rather disappointing.(198,199) A 2014 systematic review and meta-analysis included 18 studies in both adults and children.”
Sbahi, H., & Di Palma, J. A. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000087 · Cited by 75
“It has been observed that some patients develop selflimited fever and temporary elevation of CRP and IL-6 following FMT, but were considered non-significant, as patients did not deteriorate.(82) 83 Deaths have been reported following FMT, but were not related to FMT, rather were due to the chronic progressive comorbid…”
ResultFecal Microbiota Transplantation for Inflammatory Bowel Disease.
Lopez, J., & Grinspan, A. M. (2016) · PubMed · Cited by 114
Hudson, L. E., Anderson, S. E., Corbett, A. H., & Lamb, T. J. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00049-16 · Cited by 85
“alterations in their gut microbiomes (284).”
Qi, Q., Liu, Y.-N., Jin, X., Zhang, L.-S., Wang, C., Bao, C.-H., Liu, H.-R., Wu, H.-G., & Wang, X.-M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i28.3130 · Cited by 79
Damman, C. J., Brittnacher, M. J., Westerhoff, M., Hayden, H. S., Radey, M., Hager, K. R., Marquis, S. R., Miller, S. I., & Zisman, T. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133925 · Cited by 74
Slattery, J., Macfabe, D. F., & Frye, R. E. (2016) · Clinical Medicine Insights: Pediatrics · doi:10.4137/cmped.s38338 · Cited by 71
Step-up fecal microbiota transplantation (FMT) strategy
Cui, B., Li, P., Xu, L., Peng, Z., Xiang, J., He, Z., Zhang, T., Ji, G., Nie, Y., Wu, K., et al. (2016) · Gut Microbes · doi:10.1080/19490976.2016.1151608 · Cited by 71
Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease
Vaughn, B. P., Rank, K. M., & Khoruts, A. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.07.026 · Cited by 70
Fecal microbiota transplantation for the treatment of Clostridium difficile infection
Rao, K., & Safdar, N. (2016) · Journal of Hospital Medicine · doi:10.1002/jhm.2449 · Cited by 70
Zhang, M., Liang, Y., Zhang, Y., Zhang, Y., Wang, N., Zhou, Y., Wang, Y., Cui, M., Yu, Z., Zhang, M., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.152842 · Cited by 78
Fecal microbiota transplantation for ulcerative colitis: a prospective clinical study
Tian, Y., Zhou, Y., Huang, S., Li, J., Zhao, K., Li, X., Wen, X., & Li, X.-A. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1010-4 · Cited by 67
Schierová, D., Březina, J., Mrázek, J., Fliegerova, K. O., Kvasnová, S., Bajer, L., & Drastich, P. (2020) · Cells · doi:10.3390/cells9102283 · Cited by 72
“FMT resulted in increased levels of certain beneficial taxa such as Faecalibacterium prausnitzii and other butyrate-producing bacteria belonging mainly to the families Lachnospiraceae and Ruminococcaceae of the phylum Firmicutes [12,16,19,20].”
BackgroundResultInfluentialBugging inflammation: role of the gut microbiota
Shen, S., & Wong, C. H. Y. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.12 · Cited by 81
Intestinal microbiome as a novel therapeutic target for local and systemic inflammation
Uchiyama, K., Naito, Y., & Takagi, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.006 · Cited by 72
Russell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64
Clinical Evidence for the Microbiome in Inflammatory Diseases
Slingerland, A. E., Schwabkey, Z. I., Wiesnoski, D. H., & Jenq, R. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00400 · Cited by 70
“Six of six patients demonstrated clinical improvement within 2 weeks of a single transplant, with sustained improvement at 3 months observed in two patients (81).”
BackgroundIBD and the Gut Microbiota—from Bench to Personalized Medicine
Bellaguarda, E., & Chang, E. B. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0439-z · Cited by 67
Probiotics: a proactive approach to health. A symposium report
Thomas, L. V., Suzuki, K., & Zhao, J. (2015) · British Journal of Nutrition · doi:10.1017/s0007114515004043 · Cited by 59
Fecal microbiota transplant – a new frontier in inflammatory bowel disease
Sunkara, T., Rawla, P., Ofosu, A., & Gaduputi, V. V. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s176190 · Cited by 71
“18,57,64 The route of administration seems to affect the side effects profile.”
Stadlbauer, V., Leber, B., Lemesch, S., Trajanoski, S., Bashir, M., Horvath, A., Tawdrous, M., Stojakovic, T., Fauler, G., Fickert, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141399 · Cited by 59
“Approximately 175mg of stool was homogenized in as described previously in Kump et al. 2013.”
Self-citationFecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis
Uygun, A., Ozturk, K., Demirci, H., Oger, C., Avci, I. Y., Turker, T., & Gulsen, M. (2017) · Medicine · doi:10.1097/md.0000000000006479 · Cited by 58
“Clinical studies have shown that several changes in phylum level of gut microbiota composition, including a decrease of Firmicutes and Bacteriodetes and a concomitant increase of Proteobacteria and Actinobacteria, are related to UC.([12]) However, it is still debated whether these changes are responsible for activatio…”
BackgroundRole of Emerging Campylobacter Species in Inflammatory Bowel Diseases
Kaakoush, N. O., Mitchell, H. M., & Man, S. M. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000074 · Cited by 64
“While there is increasing willingness among patients with UC to consider FMT as a treatment option,(17) clinical remission is not always achieved despite successful adoption of the donor microbiota profile in patients with chronic active UC.(18) This could suggest that the dysbiotic microbiota is not completely remove…”
BackgroundInfluentialFecal microbiota transplantation for ulcerative colitis
Matsuoka, K. (2020) · Immunological Medicine · doi:10.1080/25785826.2020.1792040 · Cited by 63
Rao, K. K., & Higgins, P. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000793 · Cited by 59
“UC did note transient clinical improvement in all of them following FMT, but none achieved remission.(138) Two RCTs have been published on the use of FMT for UC and both were stopped early due to futility, although the enrolled patients were allowed to complete the studies.”
Wurm, P., Spindelboeck, W., Krause, R., Plank, J., Fuchs, G., Bashir, M., Petritsch, W., Halwachs, B., Langner, C., Högenauer, C., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002310 · Cited by 55
“Seventytwo days after onset of diarrhea, FMT was performed according to a recently described protocol on compassionate use basis (9).”
MethodSelf-citation
Metadata
- Authors
- Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., Gorkiewicz, G., & Högenauer, C.
- Affiliations
- Medical University of Graz (AT)
- Hospital of the Brothers of St. John of God (AT)
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09
- Volume
- 19
- Issue
- 10
- Pages
- 2155-2165
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W1983728610
- Cited by
- 235
- References
- 49
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 17 · 2019: 16 · 2018: 19 · 2017: 28 · 2016: 32 · 2015: 41 · 2014: 35 · 2013: 6
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- fecal microbiota transplantation, ulcerative colitis
- MeSH terms
- Adolescent, Adult, Biological Therapy, Chronic Disease, Clostridium Infections, Colitis, Ulcerative, Feces, Female, Follow-Up Studies, Humans, Intestines, Male, Middle Aged, Phylogeny, Prognosis, Remission Induction, RNA, Ribosomal, 16S, Transplantation, Metagenome, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.